

PRODUCT INFORMATION

| | |
|---|---|
| Clone ID | 1H2 |
| Target | CL2A |
| Synonyms | N.A. |
| Host Species | Rabbit |
| Description | PE-conjugated Anti-CL2A(ADC linker) antibody(1H2); Rabbit mAb |
| Delivery | 3-4 weeks |
| Uniprot ID | N.A. |
| IgG type | Rabbit IgG |
| Clonality | Monoclonal |
| Reactivity | N.A. |
| Applications | Flow Cyt |
| Recommended Dilutions | Flow Cyt 1:100 |
| Purification | Purified from cell culture supernatant by affinity chromatography |
| Formulation & Reconstitution | Liquid□PBS with 0.05% Proclin300, 1% BSA |
| Storage & Shipping | Store at 2°C-8°C for 6 months |
| Background | CL2A is a crucial component in antibody-drug conjugate (ADC) therapy, acting as a chemical linker that connects a potent DNA topoisomerase I inhibitor, SN-38, to an antibody. Representing Cysteine-Linked 2-Aminoethyl, CL2A features a complex structure with a PEG8 chain, a triazole ring, a PABC-peptide, and a maleimide group. The maleimide group binds to a cysteine residue on the antibody, facilitating targeted drug delivery. Designed to release SN-38 in acidic cancer cell environments, CL2A induces DNA damage and cell death. This versatile linker is employed in ADCs targeting various antigens like Trop-2 or HER2, tailored to specific cancer types. |
| Usage | Research use only |
| Conjugate | PE-conjugated |

